Abstract | BACKGROUND AND AIM: METHODS: UNITY-4 (NCT02170727) was an open-label, two-cohort study in which 169 patients, treatment-naive (n = 138) or treatment-experienced (n = 31), received twice-daily DCV-TRIO for 12 weeks with 24 weeks of post-treatment follow-up. The primary efficacy end point was sustained virologic response at post-treatment week 12 (SVR12) in treatment-naive patients. RESULTS: Eighty-eight (52%) patients were men, 81 (48%) Taiwanese, 78 (46%) Korean, and 10 (6%) Russian; 23 (14%) had compensated cirrhosis, and 52 (31%) were IL28B (rs1297860) non-CC genotype. Baseline resistance-associated NS5A polymorphisms (L31 and/or Y93) were detected in 25/165 (15%) patients with available genotype-1 sequencing data. SVR12 was achieved by 98.6% (136/138; 95% confidence interval: 94.9-99.8%) of treatment-naive and 100% (31/31; 95% confidence interval: 88.8-100%) of treatment-experienced patients. Both virologic failures were found to be infected with hepatitis C virus genotype-6g; 100% SVR12 was observed for genotype-1a (n = 8) and genotype-1b (n = 157). Two patients experienced serious adverse events. Eight (5%) patients experienced reversible grade 3/4 alanine aminotransferase or aspartate aminotransferase elevations, leading to discontinuation in four (2%); all achieved SVR12. There were no grade 3/4 total bilirubin increases and no deaths. CONCLUSIONS: Twelve weeks of DCV-TRIO was well tolerated and provided 100% SVR12 in treatment-naive and treatment-experienced patients with genotype-1 infection, with or without cirrhosis, including those with baseline NS5A-L31 or NS5A-Y93 resistance-associated substitutions.
|
Authors | Jia-Horng Kao, Ming-Lung Yu, Cheng-Yuan Peng, Jeong Heo, Chi-Jen Chu, Ting-Tsung Chang, Youn-Jae Lee, Tsung-Hui Hu, Ki Tae Yoon, Seung Woon Paik, Young Suk Lim, Sang Hoon Ahn, Vasily Isakov, Fiona McPhee, Wenhua Hu, Eugene Scott Swenson, Philip D Yin, Michelle Treitel |
Journal | Journal of gastroenterology and hepatology
(J Gastroenterol Hepatol)
Vol. 32
Issue 12
Pg. 1998-2005
(Dec 2017)
ISSN: 1440-1746 [Electronic] Australia |
PMID | 28370350
(Publication Type: Journal Article)
|
Copyright | © 2017 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd. |
Chemical References |
- 8-cyclohexyl-N-((dimethylamino)sulfonyl)-1,1a,2,12b-tetrahydro-11-methoxy-1a-((3-methyl-3,8-diazabicyclo(3.2.1)oct-8-yl)carbonyl)cycloprop(d)indolo(2,1-a)(2)benzazepine-5-carboxamide
- Benzazepines
- Carbamates
- Drug Combinations
- Imidazoles
- Indoles
- Isoquinolines
- Pyrrolidines
- Sulfonamides
- Valine
- daclatasvir
- asunaprevir
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Benzazepines
(administration & dosage)
- Carbamates
- Cohort Studies
- Drug Combinations
- Female
- Follow-Up Studies
- Genotype
- Hepacivirus
(genetics)
- Hepatitis C, Chronic
(drug therapy, virology)
- Humans
- Imidazoles
(administration & dosage)
- Indoles
(administration & dosage)
- Isoquinolines
(administration & dosage)
- Male
- Middle Aged
- Pyrrolidines
- Republic of Korea
- Russia
- Sulfonamides
(administration & dosage)
- Taiwan
- Treatment Outcome
- Valine
(analogs & derivatives)
- Young Adult
|